ACE2 and infection: Because there were cases of infection with SARS-CoV-2 presenting mutations of the RBD, resulting in a superior resistance to neutralize the antibodies and increase the affinity to ACE2, different monoclonal antibodies were proposed as viable treatment options (i.e., bamlanivimab, bamlanivimab/etesevimab, regdansimab, casirivimab/imdevimab, sotrovimab, etc.)[15].